Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations

Contemporary Clinical Trials Communications(2021)10.1016/j.conctc.2021.100733Source: DataRank Database

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations is a research paper published in Contemporary Clinical Trials Communications (2021). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.18)OA: goldTopics (23)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Booil Jo ORCID,Thomas Frazier ORCID,Patricia Klaas,Robyn M. Busch ORCID,Kira A. Dies ORCID

Live enrichment

PubMed:33644493 OpenAlex:https://openalex.org/W3127159961

NICHD NIH HHS

Grant: P50 HD105351

NINDS NIH HHS

Grant: U54 NS092090

FWCI

1.18

Citation Percentile

0.8%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.conctc.2021.100733

GOLDhttps://doi.org/10.1016/j.conctc.2021.100733

publisherhttps://doi.org/10.1016/j.conctc.2021.100733

publisherhttps://api.elsevier.com/content/article/PII:S2451865421000351?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451865421000351?httpAccept=text/plain

Fields of Study

PI3K/AKT/mTOR signaling in cancerProtein Tyrosine PhosphatasesCellular transport and secretionMedicine

Keywords

EverolimusPlaceboNeurocognitiveClinical endpointAdverse effectMedicinePTENRandomized controlled trialInternal medicineOncologyPsychologyPsychiatryCognitionPathologyBiologyPI3K/AKT/mTOR pathwayAutism spectrum disorderNeurobehavior and neurocognitionPTEN hamartoma tumor syndrome

Sustainable Development Goals

SDG 0: Quality Education